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The London Declaration (2012) was formulated to support and focus the control and elimi-
nation of ten neglected tropical diseases (NTDs), with targets for 2020 as formulated by the
WHO Roadmap. Five NTDs (lymphatic filariasis, onchocerciasis, schistosomiasis, soil-
transmitted helminths and trachoma) are to be controlled by preventive chemotherapy
(PCT), and four (Chagas’ disease, human African trypanosomiasis, leprosy and visceral
leishmaniasis) by innovative and intensified disease management (IDM). Guinea worm, vir-
tually eradicated, is not considered here. We aim to estimate the global health impact of
meeting these targets in terms of averted morbidity, mortality, and disability adjusted life
years (DALYs).
Methods
The Global Burden of Disease (GBD) 2010 study provides prevalence and burden esti-
mates for all nine NTDs in 1990 and 2010, by country, age and sex, which were taken as
the basis for our calculations. Estimates for other years were obtained by interpolating
between 1990 (or the start-year of large-scale control efforts) and 2010, and further extrapo-
lating until 2030, such that the 2020 targets were met. The NTD disease manifestations con-
sidered in the GBD study were analyzed as either reversible or irreversible. Health impacts
were assessed by comparing the results of achieving the targets with the counterfactual,
construed as the health burden had the 1990 (or 2010 if higher) situation continued
unabated.
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Principle Findings/Conclusions
Our calculations show that meeting the targets will lead to about 600 million averted DALYs
in the period 2011–2030, nearly equally distributed between PCT and IDM-NTDs, with the
health gain amongst PCT-NTDs mostly (96%) due to averted disability and amongst IDM-
NTDs largely (95%) from averted mortality. These health gains include about 150 million
averted irreversible disease manifestations (e.g. blindness) and 5 million averted deaths.
Control of soil-transmitted helminths accounts for one third of all averted DALYs. We con-
clude that the projected health impact of the London Declaration justifies the required
efforts.
Author Summary
Neglected tropical diseases (NTDs) are a group of infectious diseases that occur mostly in
poor, warm countries. NTDs are caused by various bacteria and parasites, such as worms.
They can either be cured or prevented through drugs and other interventions, such as con-
trol of insects that spread the infection. The London Declaration is a statement by various
organizations, including the World Health Organization (WHO) and pharmaceutical
companies that donate the necessary drugs. The declaration endorses targets for disease
reductions by 2020, as recently formulated in the WHO Roadmap, to be achieved by rigor-
ous application of available interventions. We explore how much health can be gained if
these targets are indeed achieved. We estimate that in such case 5 million deaths can be
averted before 2030 and also that huge reductions in ill-health and disability can be real-
ized. Over the period 2011–2030, a total health gain would be accomplished of about 600
million disability adjusted life years (DALYs) averted. DALYs are a measure of disease
burden, consisting of life years lost and years lived with disability. This enormous health
gain seems to justify similar investments as for e.g. HIV or malaria control.
Introduction
Neglected tropical diseases (NTDs) are considered a special category of infectious diseases, dis-
tinct from the major killers HIV, tuberculosis and malaria, which have been the main focus of
attention and funding for developing countries over the past decades. NTDs are largely con-
fined to (sub)tropical resource-constrained regions, where they cause substantial morbidity,
disability and even mortality, as documented by the recent Global Burden of Disease (GBD)
estimates [1–4], and consequently have high socioeconomic impact [5,6]. Most NTDs are
either curable or preventable, but in practice there exist major barriers to the effective imple-
mentation of control. Fortunately, international commitment to NTD control has rapidly
increased in recent years. In 2012, the World Health Organization (WHO) formulated a ‘Road-
map’ towards ambitious control and elimination targets [7]. By endorsing the London Declara-
tion on NTDs, several private and public sector organizations committed to meet those targets
[8]. For five NTDs—lymphatic filariasis (LF), onchocerciasis, schistosomiasis, soil-transmitted
helminths (STH) and trachoma—the primary control strategy is preventive chemotherapy
(PCT). For four other NTDs—Chagas’ disease, human African trypanosomiasis (HAT), lep-
rosy and visceral leishmaniasis (VL)–control programs rely on case detection with innovative
and intensified disease management (IDM), sometimes in combination with other measures
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such as vector control. Guinea worm (dracunculiasis) is confined to just a few residual foci in
Africa and close to being eradicated. For LF, trachoma, HAT and leprosy the target is elimina-
tion by 2020, and for the others it is currently control [7,9].
The London Declaration was formulated to accelerate progress towards the WHO Roadmap
targets by sustaining or expanding existing drug donation initiatives; providing funding to sup-
port NTD programs, strengthen drug distribution, and research and development; and
enhancing collaboration and coordination on NTDs at (inter)national levels [8]. To further
motivate and justify these efforts it is important to know their expected health gains. We there-
fore aim to estimate the global health impact of meeting the WHO Roadmap targets in terms
of averted morbidity and mortality, expressed in years lived with disability (YLD), years of life
lost (YLL), and disability adjusted life years (DALYs). YLD reflects the number of prevalent
cases of each considered disease manifestation multiplied by a disease-specific disability weight
between 0 (perfect health) and 1 (equivalent to death), whereas YLL reflects the number of
deaths times a standard life expectancy at the age of death in years. The number of DALYs is
the sum of both measures (DALYs = YLD + YLL).
Methods
Data sources
Two datasets were used in our calculations. First, the GBD-2010 estimates regarding NTDs
were made available to us by the Institute for Health Metrics and Evaluation (IHME), Seattle,
USA [3,10]. Second, UNPOP demographic data and projections were obtained from the website
of United Nations Department of Economic and Social affairs [11]. The GBD-2010 data consist
of three burden estimates: prevalent cases, years lived with disability (YLD) and years of life lost
(YLL). These estimates were available for 1990 and 2010, per country, age group and sex. Preva-
lent cases were provided per disease manifestation (sequela), whereas YLD and YLL were only
provided as totals per NTD. Table 1 gives an overview of all 31 sequelae considered in the GBD
calculations for the London Declaration NTDs. Guinea worm was not included in the GBD
study and is therefore not considered here. For STH, burden estimates were available for ascari-
asis, hookworm disease and trichuriasis separately. Background documents justifying and
describing the underlying assumptions of the GBD estimates, including disability weights, were
also kindly made available to us. GBD estimates were structured according to the following age
groups: 0–6 days, 7–27 days, 28–364 days, 1–4 years, 5–9 years, . . ., 75–79 years, and 80+ years.
We combined the four youngest age groups into a 0–4 years group. For irreversible sequelae
(see below), the number of prevalent cases was redistributed into 1-year age groups, using a
smoothing method that minimizes the squared differences between successive years, under the
constraint that 5-years totals equal the available data. The demographic data were already avail-
able in 1-year age groups.
General approach
The GBD estimates of the number of prevalent cases for all 31 sequelae and 5 causes of death
(HAT, VL, STH-ascariasis, Chagas’ disease and schistosomiasis) in 1990 and 2010 were taken
as the basis for our calculations. Estimates for other years were obtained by interpolating
between 1990 and 2010, and further extrapolated until 2030, under the assumption that the
2020 WHO Roadmap targets were met and sustained beyond 2020. Health impacts were
assessed by comparing the results of achieving the targets with the counterfactual, construed as
the health burden had the 1990 situation continued unabated. Prevalent cases (both remaining
and counterfactual) were translated to YLD and YLL, and summed to arrive at DALYs. The
Health Gains of NTD Control or Elimination
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Table 1. The 31 sequelae (categorized as either reversible or irreversible) and associated mortality in the Global Burden of Disease 2010 study for
the ten London Declaration NTDs, except Guinea worm. The bold numbers reflect the years lived with disability (YLD) and years of life lost (YLL) for each
NTD in 2010, as estimated by the GBD 2010 study [1–4]. The excess mortality rate (μ*) was chosen to reflect the severity of the sequela. The average disabil-
ity weights were used to relate YLD to prevalent cases in our calculations for NTDs with multiple sequelae. Salomon et al. [24] provide more information
about disability weights and lay explanations of sequelae. (a) The original GBD value for LF was 2.74 million YLD, but as Cambodia, Federated States of
Micronesia, Maldives, Samoa, Sri Lanka, Togo, Tonga, Vanuatu, and Vietnam had reached elimination before 2010, their remaining burden (total of 0.04 mil-
lion YLD) was removed from our calculations. (b) The GBD values for leprosy were based on a recalculation; see methods section. (c) A disability weight
(DW = 0.097) for visceral leishmaniasis was needed to distinguish it from cutaneous leishmaniasis (DW = 0.013), as both were combined as leishmaniasis in
the YLD values available from GBD; YLL due to leishmaniasis was assumed to be fully caused by visceral leishmaniasis.
NTD (YLD and YLL in millions from the Global Burden of Disease 2010 study)
Sequela Reversible/Irreversible Excess mortality rate (μ*) Average disability weight
Lymphatic ﬁlariasis (YLD: 2.70) a
Lymphedema Irreversible 0.0 0.110
Hydrocele due to lymphatic ﬁlariasis Irreversible 0.0 0.097
Onchocerciasis (YLD: 0.49)
Skin disease due to onchocerciasis Reversible NA 0.079
Vision loss due to onchocerciasis Irreversible 0.05 0.101
Schistosomiasis (YLD: 2.99, YLL: 0.32)
Schistosomiasis (i.e. symptomatic infection) Reversible NA 0.005
Mild diarrhea due to schistosomiasis Reversible NA 0.061
Anemia due to schistosomiasis Reversible NA 0.036
Hepatomegaly due to schistosomiasis Reversible NA 0.012
Hematemesis due to schistosomiasis Irreversible 0.05 0.323
Ascites due to schistosomiasis Irreversible 0.05 0.123
Dysuria due to schistosomiasis Reversible NA 0.012
Bladder pathology due to schistosomiasis Irreversible 0.05 0.012
Hydronephrosis due to schistosomiasis Reversible NA 0.012
STH—Ascariasis (YLD: 1.11, YLL: 0.20)
Ascariasis infestation Reversible NA 0.030
Severe wasting due to ascariasis Reversible NA 0.127
Mild abdominopelvic problems due to ascariasis Reversible NA 0.012
STH—Hookworm disease (YLD: 3.19)
Hookworm infestation Reversible NA 0.030
Severe wasting due to hookworm disease Reversible NA 0.127
Mild abdominopelvic problems due to hookworm disease Reversible NA 0.012
Anemia due to hookworm disease Reversible NA 0.032
STH—Trichuriasis (YLD: 0.64)
Trichuriasis infestation Reversible NA 0.030
Severe wasting due to trichuriasis Reversible NA 0.127
Mild abdominopelvic problems due to trichuriasis Reversible NA 0.012
Trachoma (YLD: 0.33)
Trachoma Irreversible 0.05 -
Chagas’ disease (YLD: 0.31, YLL: 0.24)
Acute Chagas’ disease Reversible NA 0.053
Chronic heart disease due to Chagas’ disease Irreversible 0.10 0.078
Chronic digestive disease due to Chagas’ disease Irreversible 0.0 0.078
Heart failure due to Chagas’ disease Irreversible 0.10 0.139
Human African trypanosomiasis (YLD: 0.01, YLL: 0.55)
African trypanosomiasis Reversible NA -
Leprosy (YLD: 0.04) b
(Continued)
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health impact of reaching the targets was expressed as DALYs averted over the decades 2011–
2020 and 2021–2030.
All calculations were carried out in duplicate in Microsoft Excel, and verified using R. All
results (totals and country-specific values), underlying calculations and assumptions are avail-
able as an open-access web-based dissemination tool (https://erasmusmcmgz.shinyapps.io/
dissemination/). A detailed step-wise explanation of our methodology is given below.
Trends for reversible and irreversible sequelae
Sequelae were first categorized as either reversible or irreversible (Table 1), depending on
whether treatment of the underlying infection would remove the sequelae in a relatively short
time, say, within a couple of years at most. For all reversible sequelae, interventions were con-
sidered to affect their prevalence, while for irreversible sequelae this was their incidence. Linear
interpolation (at the log-scale for irreversible sequelae) was carried out between 1990 (or the
start-year of large-scale control efforts) and 2010 for prevalence rates (i.e. the number of preva-
lent cases divided by population size) per sequela, country, age group and sex. Absolute num-
bers were then calculated from these interpolated prevalence rates, using the demographic
UNPOP data. For 2020 (and beyond), WHO Roadmap targets were interpreted in terms of
prevalence (for reversible sequelae) or incidence (for irreversible sequelae) levels, based on dis-
cussions with—mostly WHO—disease experts (Table 2). Trends in incidence and prevalence
during the intervening years (usually 2010–2020) were obtained through linear interpolation
between the 2010 levels (GBD data) and the interpreted targets. We then translated the calcu-
lated trends into absolute numbers of remaining cases using UNPOP projections for the period
2011–2030, and compared this with the counterfactual situation of no additional control
efforts, to assess the impact of meeting the targets. The counterfactual was construed as the
health burden that would have been expected had the 1990 epidemiological situation (i.e. dis-
ease incidence or prevalence) continued unabated. Whenever the 2010 prevalence of a sequela
exceeded that of 1990, we took 2010 as the counterfactual.
Incidence and prevalence calculations for irreversible sequelae
Interpolation for irreversible sequelae, such as blindness as a result of onchocerciasis, was car-
ried out at the level of incidence, because even after elimination of infection these sequelae will
persist until the death of the last patient. The annual incidence density λ(a,t) at age a and calen-





¼ lða; tÞ  sða; tÞ þ ½1  sða; tÞ  mða; tÞ  sða; tÞ
where s(a,t) denotes the susceptible fraction (i.e. 1 –prevalence) of the population and μ(a,t)
the excess mortality rate among those affected. In a stable endemic situation (i.e. without
cohort effect, thus @s(a,t)/@t = 0) and without excess mortality (i.e. μ(a,t) = 0), λ(a,t) can be
Table 1. (Continued)
NTD (YLD and YLL in millions from the Global Burden of Disease 2010 study)
Sequela Reversible/Irreversible Excess mortality rate (μ*) Average disability weight
Disﬁgurement due to leprosy Irreversible 0.0 -
Visceral leishmaniasis (YLD: 0.01, YLL: 3.19)
Visceral leishmaniasis Reversible NA 0.097 c
doi:10.1371/journal.pntd.0004386.t001
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Table 2. Interpretations of WHORoadmap targets [7] as used in our calculations. All country-specific assumptions for each NTD are provided here:
https://erasmusmcmgz.shinyapps.io/dissemination/.
Lymphatic ﬁlariasis Target: By 2020, 70% of countries will have been veriﬁed as free of transmission and 30% will have entered
post-intervention surveillance.
Interpretation: The PCT database [25] provides start and end years of the intervention program per country.
The incidence of both chronic manifestations (lymphedema and hydrocele) is assumed to linearly decrease to
zero, one year before the anticipated last treatment round in each country.
Onchocerciasis Target: To eliminate onchocerciasis where feasible (without a speciﬁed target year).
Interpretation: Interventions will continue until the end year of interventions as estimated by APOC [26];
prevalence of skin disease and incidence of vision loss reach zero two years before the end year of
interventions.
Schistosomiasis Target: Elimination of transmission in certain regions and countries by 2015 or 2020. Global elimination in
2025 as a public health problem. In 2020, 75% national coverage is reached in all the countries requiring
preventive chemotherapy for schistosomiasis.
Interpretation: Global elimination in 2025, therefore in all countries prevalence of reversible and incidence of
irreversible sequelae will go down to zero in 2025. The general start year of interventions is 2001, the same
year as the WHA resolution on STH and schistosomiasis [27].
STH (ascariasis, hookworm disease and
trichuriasis)
Target: 100% of countries requiring preventive chemotherapy for STH have achieved 75% national mass drug
administration coverage of school-aged children (SAC) and pre-SAC by 2020.
Interpretation: The pre-SAC and SAC (ages 5–14) will have 0% prevalence of morbidity by 2025. There will
be 10% remaining prevalence of morbidity in the non-treated groups (0–4 and 15+) by the year 2025, relative
to the STH level in 2010. Mortality due to ascariasis will be 0% in 2025, for all age groups. The general starting
year of interventions is 2001, the same year as the WHA resolution on STH and schistosomiasis [27].
Trachoma Target: Global elimination as a public health problem in 2020. All countries will have achieved the ultimate
intervention goal and be free from blinding trachoma as a public health problem.
Interpretation: Incidence of vision loss caused by trachoma will go down to zero in country speciﬁc years.
Three WHO documents [7,28,29] provide most start years of intervention and target years of elimination.
Chagas’ disease Target: To eliminate transmission through blood transfusion in the America’s, Europe and Western Paciﬁc by
2015. To eliminate peri-domiciliary infestation in Latin America by 2020, but surveillance and control of oral
transmission and congenital infection need to be sustained.
Interpretation: For acute Chagas’ disease the prevalence will linearly decrease to 10% of the GBD 2010
value in 2020, and remain 10% onwards. This 10% reﬂects remaining burden due to infections from the
sylvatic cycle. For chronic heart disease, chronic digestive disease and heart failure, incidence in 2020 will be
10% of that in 2010, and remain 10% onwards. The GBD data about Chagas’ disease only concern countries
in Latin America, so no speciﬁc assumptions are needed for the rest of the world.
Note: There are great concerns about the reliability of the GBD ﬁgures, as well as the feasibility of the London
Declaration and associated WHO targets [30].
HAT Target: Achieve elimination of >90% of foci by 2020. The global number of new cases reported annually for
2020 is <2000.
Interpretation: There are exactly 2000 cases in 2020, and this number will subsequently decline to 0 in 2030.
From 2020 onwards, all remaining cases will be detected and treated, meaning that HAT mortality is zero in
2020 and beyond. The overall number of prevalent cases in 2020 is 2.5% of the level in 2010.
Explanation: In 2010, 9103 people died because of HAT according to YLL data of GBD 2010. By multiplying
the number of people that died in 2010 by 3 (the burden before dying is assumed to last on average for three
years in the GBD calculations) we arrive at 27,307 prevalent cases in 2010 that will eventually die because of
HAT. The total point prevalence of HAT in 2010 is provided by the GBD: 36,863. This means that about 75%
(27,307 out of 36,863) of prevalent cases will eventually die, whereas the remaining 25% (9,554 out of 36,863)
will survive. The 9,554 surviving prevalence cases multiplied by 2 results in 19,108 new detected and
successfully treated cases in 2010 (given the GBD assumption that disease lasts 6 months before treatment).
Thus, on a global level there will be a decrease from 19,108 new surviving cases in 2010 down to 2000 new
surviving cases in 2020, so roughly a decrease to 10% of the level in 2010. This decrease applies to the
number of surviving prevalent cases, which is 25% of the total. This means that the overall number of
prevalent cases will go down to 10% times 25% = 2.5% of the level in 2010, as the 75% of cases that
eventually die will become 0.
Note: The number of new detected and treated cases (19,108) and the number of new cases that will die
(9,554) adds up to 28,211 new cases in 2010, which is substantially higher than what is known in WHO
records [31]: 7139 new reported cases in 2010.
Leprosy Target: Global interruption of transmission by 2020. Reduction of grade 2 disabilities in newly detected cases
to below 1/million population at global level by 2020.
(Continued)
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obtained from a single cross-sectional survey by taking the differences in the logarithmic age
proﬁle of the fraction susceptible. However, because the cross-sectional age proﬁles of GBD
1990 and 2010 for each sequela differed, we annualized the differences (on a logarithmic scale)
in these proﬁles to obtain an estimate for @s(a,t)/@t. We further assumed the excess mortality
rate to be independent of age and calendar time, and have a pre-set value μ = 0.0, 0.05 or 0.10,
dependent on the severity of the sequela (Table 1). The value of μ was chosen after consulta-
tion of the disease experts and crudely reﬂected the mortality rates as used in the GBD calcula-
tions. The resulting incidences were calculated back to prevalences (of remaining cases) by
‘exposing’ cohorts to the derived age and time-speciﬁc incidence densities and excess mortality
rates.
Morbidity calculations: Years living with disability (YLD)
Predicted prevalent cases for each sequela were then translated to YLD, using two matrices of
multiplication factors (one for the year 1990 and one for 2010) that we had derived from the
GBD data as follows. Whenever an NTD had one sequela (e.g. trachoma), the GBD YLDs in
1990 and 2010 were divided by the number of prevalent cases in the same year to arrive at
country, age and sex-specific multiplication factors that capture disability weights, the underly-
ing case-mix (e.g. severe vs. mild disability, where applicable), and correction of burden esti-
mates for co-morbidity, as used in the GBD 2010 study [2]. For NTDs with multiple sequelae
(e.g. onchocerciasis) we followed the same procedure, but using a weight for each sequela
based on an estimate of the average disability weight using GBD documentation (Table 1),
because the YLD data provided by the GBD study did not separate the contributions of differ-
ent sequelae. We treated all multiplication factors as constants. Remaining cases after 2010
Table 2. (Continued)
Interpretation: The incidence of disﬁgurement due to leprosy has decreased in 2020 to 37% of the level in
2010, and will further reduce to 0% in 2030, in order to account for the target of global interruption of
transmission by 2020.
Explanation: According to the 2010 GBD data, the incidence of all newly detected cases was 318,876, of
which 6% (19,132) had grade 2 disability [12]. This is 2.7/1 million globally. According to the WHO target, this
should be reduced to 1/1 million in 2020, representing a reduction to approximately 37% of the level in 2010,
or 7,086 incident cases in 2020.
Note: See main text for our recalculations to arrive at grade 2 disability prevalences.
Visceral leishmaniasis Target: On the Indian subcontinent (ISC), 1/10,000 new cases at (sub)district level per year by 2020; globally,
100% detection and treatment of VL.
Interpretation: On ISC there will be a prevalence reduction to 5% of the 2010 situation, which will remain at
5% until 2030. Elsewhere, the prevalence of 2010 will remain unaltered. Morbidity in 2020 will have become
25% (Africa), 0.3% (ISC) and 10% (elsewhere) of the level in 2010, and remain constant thereafter.
Explanation about prevalence on ISC: WHO reports approximately 20/10,000 new VL cases per year on
ISC in 2010. Therefore, the target of 1/10,000 will be a reduction to 5% of the 2010 situation. This 5% will also
apply to the prevalent cases.
Explanation about trends in death: In 2010, 51,485 people died because of VL according to YLL data of
GBD 2010. Also, worldwide there were 67,721 prevalent cases, which correspond to 270,884 new cases,
given the GBD-assumed 3 month average duration of VL. Thus, in 2010 on average 19% of the people with
VL died globally. According to the WHO targets, death due to VL will decrease substantially, but it will not go
down to zero, as current treatment is not 100% effective [32]. We assume that in Africa 5% of the people
(even though detected and treated) with VL will die in 2020, 1% of the people with VL on the Indian
subcontinent, and 2% elsewhere. This means that in Africa the relative number of deaths (and also YLL) will
decrease to 5/19 = about 25% of the level in 2010. On the Indian subcontinent this will be 0.05 times 1/
19 = about 0.3% of the level in 2010. Elsewhere, this will be 2/19 = about 10% of the level in 2010. The
regional differences in mortality rates were based on discussions with the disease experts and particularly
reﬂect differences in treatment efﬁcacy and HIV-coinfection.
doi:10.1371/journal.pntd.0004386.t002
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were multiplied by the factors in the 2010-matrix, and for 1990–2010 an interpolation of the
multiplication factors in both matrices was used. For counterfactual cases we used the multipli-
cation factors in the 1990-matrix, or both matrices when 2010 was used as counterfactual (i.e.
similar to the approach for remaining cases).
Mortality calculations: Years of life lost (YLL)
Regarding our mortality calculations, we first translated GBD YLLs in 1990 and 2010 to actual
country, age, and sex cause-specific mortality rates, using the age and sex-specific residual life
expectancies as applied in the GBD study [1]. For HAT, VL and ascariasis, where mortality is
closely linked (in time) to infection prevalence, these rates were treated as prevalent cases (of
reversible sequelae) as described above and back-calculated to YLLs. For Chagas’ disease and
schistosomiasis, where mortality is closely linked to late sequelae, we followed a different pro-
cedure. Similar to the calculation of YLDs for NTDs with multiple sequelae, we related YLLs in
1990 and 2010 to prevalent cases of selected sequelae, using a weight representing their lethal-
ity. For schistosomiasis, mortality was related to hematemesis (weight = 50), ascites (1.0) and
schistosomiasis infestation (0.01). For Chagas’ disease, these were heart failure (10) and
chronic heart disease (1.0).
Special cases
Using the above method, some irreversible sequelae—in particular for Chagas’ disease and LF
—showed for some countries values of λ(a,t)< 0, due to unrealistic fast declines in the GBD
prevalence estimates between 1990 and 2010. Here, we chose alternative prevalences, but still
within the confidence limit (Cl) provided by the GBD study, as follows. We reduced the GBD
1990 ‘Mean’ prevalence to 0.25 ‘Mean’ + 0.75 ‘Lower Cl’, and we increased the GBD 2010
‘Mean’ prevalence to 0.25 ‘Mean’ + 0.75 ‘Upper Cl’.
The GBD 2010 estimates for leprosy appeared to be mistakenly based on overall leprosy
new case detection (incident cases) instead of prevalence of (irreversible) cases with leprosy
grade 2 disability, on which the disability weights are based. We therefore performed a recalcu-
lation to arrive at grade 2 disability prevalences as follows. First, we took from the WHO-pub-
lished global leprosy data for 2010 the proportion of newly detected cases with grade 2
disability, which was 6% [12]. Secondly, prevalence of leprosy cases with grade 2 disability in
virtual birth cohorts was accrued at a rate determined by this incidence density, while assuming
a steady-state until 1990 and a linear decreasing incidence to 2010. We further assumed that
excess mortality due to leprosy is negligible (μ = 0.0). These prevalence values constituted the
‘GBD data’ on which our calculations were based.
Results
Fig 1 shows the global trends in remaining and averted DALYs, distinguished into YLD of
reversible and irreversible sequelae and YLL. According to the original GBD 2010 data (dark-
colored bars), the health burden of onchocerciasis, STH, Chagas’ disease, HAT and VL has
clearly decreased over the period 1990 to 2010. For LF, schistosomiasis and leprosy, the abso-
lute burden has increased, but not as fast as would be expected from the counterfactual. Thus,
for these NTDs, the relative burden has decreased, when correcting for population growth.
Only for trachoma (and in some countries for schistosomiasis), the GBD-estimated burden has
increased faster than would be expected from the demographic trends over the period 1990–
2010.
Meeting the 2020 targets will lead to a substantial health-impact for all NTDs (Fig 1). It is
clearly visible that reversible sequelae (green) are disappearing faster than irreversible sequelae
Health Gains of NTD Control or Elimination
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(brown). This makes the health impact of reaching the targets for LF, trachoma and leprosy
over the first two decades somewhat less spectacular compared to that for the other NTDs, of
which the burden is mainly caused by reversible sequelae or death. Another important factor
determining the overall health impact is population growth and other demographic develop-
ments, as expressed by the counterfactual. NTDs that are prevalent in Asia (LF, STH, leprosy
and VL) show a slower rise of the counterfactual compared to the NTDs mainly confined to
Africa (onchocerciasis, trachoma and HAT) or South America (Chagas’ disease).
Overall, meeting the targets of London Declaration NTDs will avert about 600 million
DALYs in the two decades after 2010, nearly equally distributed between PCT and IDM-NTDs,
with the former mostly (96%) attributable to averted disability, whereas the latter largely (95%)
results from averted premature death (Fig 2). These health gains include about 150 million
averted irreversible disease manifestations, in particular chronic heart disease due to Chagas’
disease, bladder pathology due to schistosomiasis, and hydrocele and lymphedema due to LF
(Table 3). In addition, approximately 5 million deaths are averted, mainly from VL and HAT,
and to a lesser extent Chagas’ disease (Table 4).
Discussion
Of the 600 million DALYs overall averted in the period 2011–2030, in the ideal situation of
meeting the WHO Roadmap targets of London Declaration NTDs, about 30 million will be
realized in the year 2020, increasing to 40 million in the year 2030. This is of the same order of
magnitude as the current annual health burden of any of the ‘big three’ infectious diseases,
HIV/AIDS, TB and malaria, which accounted for about 80, 50 and 80 million DALYs,
Fig 1. Global trends of remaining and averted disability adjusted life years (DALYs) from 1990 to 2030 for nine NTDs that are part of the London
Declaration, with soil-transmitted helminths presented for ascariasis, hookworm disease and trichuriasis separately.DALYs are divided into years
of life lost (YLL) and years lived with disability (YLD), with the latter subdivided into reversible and irreversible sequelae. Estimates for remaining DALYs were
obtained by interpolating between 1990 (or the start-year of large-scale control efforts) and 2010, and further extrapolated until 2030, such that the 2020
targets of theWHORoadmap were met. Averted DALYs were assessed by comparing the results of achieving the targets with the counterfactual, construed
as the health burden had the 1990 (or 2010 if higher) situation continued unabated. The bars for 1990 and 2010 reflect the Global Burden of Disease (GBD)
data [1–4], on which all calculations were based. The boxes indicate the most significant (i.e. visible) sequelae; where multiple sequelae make part of the total
of reversible or irreversible disease (YLD) for an NTD, their relative contribution (%) to averted YLD in the period 2011–2030 is indicated. Underlying
assumptions and more detailed results, both globally and at the country-level can be found here: https://erasmusmcmgz.shinyapps.io/dissemination/
doi:10.1371/journal.pntd.0004386.g001
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respectively, in 2010 [3]. Clearly, for these three infections elimination is a more remote per-
spective than for the nine NTDs targeted by the London Declaration. Thus, the ongoing efforts
to control the big three seem to justify similar investments in NTD control. In addition, it can
be expected that for several of these NTDs control efforts will lead to a cessation of transmis-
sion over vast regions, after which further control can be discontinued and investments wound
down adding to the value of this investment for future generations.
Fig 2. Estimated overall health impact of meeting theWHORoadmap targets for nine London Declaration NTDs. Five (lymphatic filariasis,
onchocerciasis, schistosomiasis, soil-transmitted helminths and trachoma) are to be controlled by preventive chemotherapy (PCT), and four (Chagas’
disease, human African trypanosomiasis, leprosy and visceral leishmaniasis) by innovative and intensified disease management (IDM). Values are in
millions of averted DALYs per 10-year period, subdivided into years of life lost (YLL) and years lived with disability (YLD).
doi:10.1371/journal.pntd.0004386.g002
Table 3. Estimated number of averted new cases of irreversible disease (in millions) whenmeeting theWHORoadmap targets for London Declara-
tion NTDs.
NTD Sequela 2011–2020 2021–2030
Lymphatic ﬁlariasis Lymphedema 8.4 10.3
Hydrocele due to lymphatic ﬁlariasis 12.7 15.0
Onchocerciasis Vision loss due to onchocerciasis 1.8 3.3
Schistosomiasis Hematemesis due to schistosomiasis 0.1 0.4
Ascites due to schistosomiasis 0.3 0.9
Bladder pathology due to schistosomiasis 10.9 31.9
Trachoma Trachoma 3.2 6.8
Chagas’ disease Chronic heart disease due to Chagas’ disease 14.6 22.7
Chronic digestive disease due to Chagas’ disease 1.3 1.7
Heart failure due to Chagas’ disease 0.1 0.2
Leprosy Disﬁgurement due to leprosy 1.0 1.3
Total averted new cases 54.3 94.6
doi:10.1371/journal.pntd.0004386.t003
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STH accounts for one-third (34%) of the averted DALYs, almost entirely due to avoided dis-
ability. This perhaps surprising finding can be easily explained by the wide-spread distribution
of STH [13]. Importantly, approximately half (46%) of the averted STH-burden would be real-
ized in China. This brings to the fore the sensitivity of our results to the choice of counterfac-
tual. That is, our assumption that the situation of 1990 would continue unabated may be
questioned for several countries, including China, which have experienced unprecedented eco-
nomic and social development over the past decades [14]. For example, the health impact for
STH would be about halved if the situation in 2010 were used as the counterfactual, as can
roughly be concluded from Fig 1, but such a drastic correction would certainly not be reason-
able for many endemic countries in Africa and Southern Asia. On the other hand, socioeco-
nomic development may also have facilitated the spread of NTDs, in particular
schistosomiasis, of which large outbreaks followed the construction of dams and irrigation
schemes [15]. HAT perhaps follows more erratic patterns, reflecting e.g. civil unrest, war and
also ecological circumstances [16], so that the year 1990 may not be representative of the actual
counterfactual over 1990–2020. Trachoma and schistosomiasis showed large increases in GBD
prevalence from 1990 to 2010, which may well reflect an underestimation of the 1990 burden.
Consequently, this may have led to underestimating both the counterfactual and the health
impact. Another potential source of underestimation of the health impact for some NTDs may
be that the largest gains are achieved in the initial years of programs, followed by a slow down
towards the target year, as it becomes harder to reach the more marginalized populations. Fur-
thermore, by using a fixed excess mortality rate μ for irreversible sequelae (where applicable)
we may have somewhat overestimated health impacts for these sequelae as treatment is likely
to improve over time. However, since the remaining cases get older at the same time, possibly
experiencing a higher mortality, we may have introduced some underestimation as well.
Clearly, by using a uniform methodology we have introduced (perhaps occasionally substan-
tial) under or overestimation of NTD and country-specific results, but we are confident that
the overall bias in our estimated health impact of reaching the targets will be small.
Almost half (44%) of the overall health impact is attributable to averted deaths, in particular
from visceral leishmaniasis and HAT, and to a lesser extent Chagas’ disease, followed by schis-
tosomiasis and STH (ascariasis). In our calculations, we followed the GBD accounting philoso-
phy which assigns all DALYs (i.e. residual life expectancy at the age of death) resulting from a
death to the year in which it occurred [1], whereas DALYs attributable to morbidity are
accrued during the years that individuals suffer [2]. Moreover, remaining life expectancies
were based on the demography of Japan, according to the fundamental concept that all people
are entitled to the best life expectancy in the world, irrespective of e.g. country of residence and
socioeconomic status. Clearly, other methodologies might have distributed health gains differ-
ently over time.
Table 4. Estimated number of averted deaths (in millions) whenmeeting theWHORoadmap targets for the five London Declaration NTDs with
associated mortality.
NTD 2011–2020 2021–2030
Visceral leishmaniasis 0.99 50.7% 1.36 47.6%
HAT 0.70 35.7% 0.99 34.6%
Chagas’ disease 0.16 8.3% 0.29 10.2%
Schistosomiasis 0.08 4.2% 0.18 6.3%
STH—Ascariasis 0.02 1.1% 0.04 1.3%
Total averted deaths 1.96 100.0% 2.87 100.0%
doi:10.1371/journal.pntd.0004386.t004
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Our calculations depend strongly on the estimates made in the GBD study [1–3]. These esti-
mates are notably uncertain for NTDs, given the paucity of data on their geographic spread
and control. Most GBD 1990 and 2010 estimates for NTDs show very wide confidence inter-
vals, often ± 50% the mean, but sometimes with an upper confidence limit up to 5 times the
mean. As a consequence, our predictions (all based on GBD point estimates) are subject to at
least a similar degree of uncertainty. Also, the GBD disability weights used are still under heavy
debate, such as the relatively low value for blindness as compared to itching [17]. Furthermore,
our calculations are confined to the 31 sequelae considered in the GBD study, and discussions
continue about whether additional sequelae need to be considered. In particular, the choice not
to include so-called subtle morbidities, such as impaired cognitive development due to STH
and schistosomiasis, or poor mental health from stigma and discrimination due to the disfig-
urements caused by LF and leprosy, is considered an important omission by many [13,18–21].
Our results also depend upon the interpretation and formulation of the WHO Roadmap tar-
gets [7,9], which occasionally are ambiguous. Consulting disease experts at WHO has resulted
in agreement about interpretations for most NTDs, even though sometimes the targets were
considered too general or utopic.
In addition to the intrinsic value of averting human suffering and death, this health impact
of reaching the targets will also give rise to major economic and societal improvements, such as
increased productivity and avoided (often catastrophic) out of pocket payments for treatment
and care, which can be assigned monetary values. In particular, the currently ignored subtle
morbidities are likely responsible for major societal impacts.
We realize that the targets are ambitious, and may for instance be jeopardized by challenges
in drug distribution, disease surveillance and health care access. Also, systematic non-compli-
ance in mass-drug administration, population groups currently not eligible for treatment, and
development of drug or insecticide resistance could be serious threats, as demonstrated in a
recent collection of studies by the NTDModelling Consortium focusing on the question
whether we are on track to reaching the goals [22]. Furthermore, even if the targets are reached
by 2020 it is essential that control and surveillance are continued to avoid rebounding effects,
certainly for those NTDs where elimination of transmission cannot be expected.
In conclusion, NTDs together constitute a major health burden, comparable to any of the
three major infectious diseases HIV/AIDS, TB, and malaria. Achieving internationally agreed
targets of NTD control and elimination will bring about major gains in health and reductions
in human suffering. Much of this will be achieved by avoiding morbidity rather than mortal-
ity as many of the parasites involved, such as soil transmitted helminths, rarely kill their
hosts. This also implies that our impact assessment depends on the valuation of health states
as used by GBD, a valuation that inevitably is somewhat subjective and open to debate. We
did not consider the costs involved in reaching these targets, but a recent assessment demon-
strated that these are relatively modest [23], indicating that the cost-effectiveness of interven-
tions to control NTDs will likely be high. One thing is certain however: as NTDs are
disorders that disproportionately affect the poor, their control will considerably improve
global equity.
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